320,000
Participants
Start Date
May 14, 2025
Primary Completion Date
June 1, 2028
Study Completion Date
November 1, 2028
Intervention group
Subjects will be invited for a home-based screening (phase 1) that includes home-based testing; urine collection for detection of elevated albuminuria, and a heart rhythm measurement for detection of atrial fibrillation. Both home-based tests will be performed with CE-marked medical devices used according to their intended use. A subset of the population will also receive a short questionnaire. Depending on the results of the home-based tests, subjects might be invited for further screening in a diagnostic screening facility (phase 2), that includes collection of physical data, blood, and urine for the assessment of parameters that are indicative of cardiovascular disease, chronic kidney disease, diabetes type 2 or their risk factors. Participants will also receive a questionnaire. Based on the results of the diagnostic screening, participants may be referred to their GP for appropriate treatment according to the prevailing guidelines (phase 3)
Stichting Amsterdam UMC, Amsterdam
Dutch Cardiovascular Alliance
UNKNOWN
University Medical Center Groningen
OTHER
Dutch Heart Foundation
OTHER
Dutch Kidney Foundation
OTHER
Dutch Diabetes Research Foundation
OTHER
Maastricht University
OTHER
AstraZeneca
INDUSTRY
UMC Utrecht
OTHER
Radboud University Medical Center
OTHER
Siemens Healthineers Nederland BV
UNKNOWN
University of Twente
OTHER
Roche Diagnostics Nederland BV
UNKNOWN
Happitech BV
UNKNOWN
Stichting Radboud Universiteit
UNKNOWN
Stichting Netherlands Heart Institute
UNKNOWN
Topicus.Healthcare BV
UNKNOWN
Amsterdam UMC, location AMC
OTHER
Prof. Dr. Folkert W. Asselbergs
OTHER